Literature DB >> 6529532

Cimetidine alters pethidine disposition in man.

D R Guay, R C Meatherall, J L Chalmers, G R Grahame.   

Abstract

The effect of concurrent cimetidine administration on the disposition of pethidine was investigated in eight healthy male volunteers (18-31 years). The subjects received 70 mg i.v. pethidine HCl doses before and during cimetidine treatment (1200 mg/day p.o.). During cimetidine treatment, pethidine total body clearance (CL) decreased by 22% (0.611 +/- 0.101 [mean +/- s.d.] to 0.474 +/- 0.098 1 kg-1 h, P less than 0.05) and pethidine volume of distribution at steady state (Vss) decreased by 13% (4.79 +/- 0.82 to 4.16 +/- 0.75 l/kg, P less than 0.05). A cimetidine-induced reduction in pethidine oxidation to norpethidine was suggested by a 23% reduction in norpethidine area under the curve from 0 to 24 h (472 +/- 93 to 362 +/- 38 ng ml-1 h, P less than 0.05) and a 29% reduction in peak norpethidine concentration (26.7 +/- 5.3 to 18.9 +/- 1.9 ng/ml, P less than 0.05). There were no significant linear correlations of serum trough cimetidine concentration with percentage reductions in pethidine CL, pethidine Vss, norpethidine AUC (24), or norpethidine peak concentrations. It would appear that the cimetidine-pethidine kinetic interaction may be of sufficient magnitude to be clinically significant. Caution is advised when patients are treated concurrently with these two agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529532      PMCID: PMC1463672          DOI: 10.1111/j.1365-2125.1984.tb02563.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

Review 1.  Pharmacokinetics of drug disposition: hemodynamic considerations.

Authors:  G R Wilkinson
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

2.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

3.  Rate of formation of norpethidine from pethidine.

Authors:  K L Austin; J V Stapleton; L E Mather
Journal:  Br J Anaesth       Date:  1981-03       Impact factor: 9.166

4.  Evaluation of a worldwide spontaneous reporting system with cimetidine.

Authors:  T G Davis; D L Pickett; J H Schlosser
Journal:  JAMA       Date:  1980-05-16       Impact factor: 56.272

5.  Potentially lethal interaction of cimetidine and morphine.

Authors:  A Fine; D N Churchill
Journal:  Can Med Assoc J       Date:  1981-06-01       Impact factor: 8.262

6.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

7.  Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.

Authors:  H H Szeto; C E Inturrisi; R Houde; S Saal; J Cheigh; M M Reidenberg
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

Review 8.  The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.

Authors:  B A Berkowitz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Antagonism of the convulsant effects of heroin, d-propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1975-03       Impact factor: 4.030

10.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

View more
  8 in total

1.  [Not Available].

Authors:  P Löhmer; W Tolksdorf
Journal:  Schmerz       Date:  1989-03       Impact factor: 1.107

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 5.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 6.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

7.  Ranitidine does not alter pethidine disposition in man.

Authors:  D R Guay; R C Meatherall; J L Chalmers; G R Grahame; R J Hudson
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

Review 8.  Adverse reactions and interactions with H2-receptor antagonists.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.